OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The right ventricle tamed	1740
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	1123
Chymase-1: a “MAST”-er switch in COPD?	412
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	328
Missing airways, ventilation defects and conductive airway physiology in asthma	229
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	227
A breath of the future: a novel human model for COPD and beyond	225
The lung that rules the heart	191
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	156
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	149
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	146
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	146
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	144
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	137
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	134
Soteria: deliverance from harm?	132
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	126
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomised controlled trial	122
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	121
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	120
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	117
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	116
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	116
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	115
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	114

Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	112
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	111
sST2 and IL-6 predict prognosis of medically treated chronic thromboembolic pulmonary hypertension	106
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	104
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	100
Pulmonary hypertension associated with hereditary haemorrhagic telangiectasia: from genetics to clinical management	100
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	97
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	96
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	96
Associations between high-density lipoprotein cholesterol and interstitial lung abnormalities in the Korean national lung cancer screening programme	91
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	90
Reply: Rethinking the optimal cardiac output in pulmonary arterial hypertension	89
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	87
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	83
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	81
Early parenteral prostacyclin therapy enables near-normal haemodynamics and treatment de-escalation in patients with haemodynamically severe pulmonary arterial hypertension	81
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	80
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	78
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction	77
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	77
Treatment algorithm for pulmonary arterial hypertension	76
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	72
No exposure left behind: time to pay attention to children's chemical environment in lung development	72
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	71
Exciting times for trimodulin	70
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	68
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	67
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	66
CPAP recall and cancer risk: should we be concerned?	66
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	65
FEV₁Q: what (even) is normal lung function?	64
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	64
Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomized controlled trial	64
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	64
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	63
End-user global study to identify countries’ challenges and solutions in the uptake and implementation of new tuberculosis treatment regimens	62
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	61
The vascular fingerprint of the lungs: why pulmonary vessel count matters in COPD	61